SEOUL, Feb. 3 (Korea Bizwire) — South Korean biopharmaceutical firm Samsung Bioepis Co. said Thursday it has won approval from Canadian authorities for the sale of its biosimilar cancer drug Ontruzant. The Health Canada has approved Ontruzant — a biosimilar product referencing Switzerland-based Roche Holding’s Herceptin, also known as Trastuzumab — for treatment of adults [...]
SEOUL, Jan. 29 (Korea Bizwire) — A subsidiary of South Korean pharmaceutical firm Green Cross Corp. said Friday it has participated in a partnership deal worth US$1.8 billion to develop natural killer (NK) cell therapies to treat cancer. Under the collaboration, Green Cross LabCell will co-develop three kinds of chimeric antigen receptor (CAR) NK cell [...]
SHANGHAI, China, Sept. 16 (Korea Bizwire) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that it has recently entered into a global development, manufacturing and commercialization collaboration with Wigen Biomedicine, a biomedical high-tech company committed to research and development [...]